技术

技术

HIGHFIELD_onelips_horizontal

脂质结构是药物的重要组成,可能是影响药物体内作用的关键

我们制定有针对性的治疗方法,认识到人和疾病的复杂性

我们的主要临床开发项目针对癌症。癌症治疗需要多层次的方法。肿瘤微环境 (TME) 在实体肿瘤的行为和发展中起着关键作用。随着肿瘤细胞的增殖,它们与周围组织发生各种相互作用。我们的脂质疗法针对 TME 来阻止肿瘤生长。

We are also developing lipid nanoparticles (LNP) containing RNA for gene therapy These LNP-RNA complexes treat chronic autoimmune, metabolic and genetic diseases. LNP complexes are well known for immunization.  However, our LNPs are different from those used for vaccines.

Vaccine-related LNPs are designed to disintegrate for short term use in the body and produce an immune reaction.  However, HighField’s LNPs are tailored for stability, sustained circulation, minimum immune reaction and long term efficacy.  This results in longer lasting production of greater amounts of the therapeutic proteins.

 

Highfield 的优势

Our immuno-oncology and LNP platforms are built upon our unique capability to optimize components of a lipid system directed to specific disease tissue.  Combined with our proprietary system that consistently produces very high quality lipid structures , HighField can produce therapeutics with maximum efficacy and safety. 

Beating cancer with lipid-based therapeutics

一方面,我们最大限度地利用脂质体针对快速生长组织(如癌组织)的被动靶向特点。另一方面,我们通过将抗体偶联到脂质体上形成免疫脂质体来增强药物作用的特异性。

与抗体药物偶联物 (ADC) 等其他靶向治疗药物相比,我们的免疫脂质体具有更高的有效负载能力和负载的灵活性。脂质结构的大小、表面性质、结合效率以及药物的释放特性都在具体的产品开发中得到优化。 我们的疗法的设计。

我们开发了一种迭代、连续的脂质结构生产工艺。这种新颖的方法极大地提高了制剂的质量。

Treating chronic and genetic diseases with LNP gene therapies

We are creating LNP-RNA complexes that produce therapeutic proteins in the body.  These proteins treat chronic diseases such as autoimmune, genetic and metabolic disorders. Our LNP-RNA complexes create a steady long-term production of the therapeutic protein with little or no immune response.